Ignite Creation Date:
2025-12-24 @ 12:30 PM
Ignite Modification Date:
2026-01-09 @ 4:26 PM
Study NCT ID:
NCT06009861
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-06-06
First Post:
2023-08-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Sponsor:
Peking University Hospital of Stomatology
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
PKUSSIRB-202386047
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None